The authors reply

New England Journal of Medicine

Volumn 375, Issue 9, 2016, Pages 899-900

  Wedzicha, Jadwiga A ^a   Banerji, Donald ^b   Vogelmeier, Claus F ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE PROPIONATE PLUS SALMETEROL; GLYCOPYRRONIUM BROMIDE PLUS INDACATEROL; BRONCHODILATING AGENT; GLYCOPYRRONIUM; INDAN DERIVATIVE; MUSCARINIC RECEPTOR BLOCKING AGENT; QUINOLONE DERIVATIVE;

BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; FORCED EXPIRATORY VOLUME; HUMAN; LETTER; PATIENT SATISFACTION; PRIORITY JOURNAL; SPIROMETRY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

BRONCHODILATOR AGENTS; FORCED EXPIRATORY VOLUME; GLYCOPYRROLATE; HUMANS; INDANS; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; TREATMENT OUTCOME;

EID: 84985930447     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1609305     Document Type: Letter

References (5)

1. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011; 364: 1093-103.
2. Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): A randomised, double-blind, parallel-group study. Lancet Respir Med 2013; 1: 199-209.
3. Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: Two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 2013; 1: 210-23.
4. Wilkinson TM, Donaldson GC, Hurst JR, Seemungal TA, Wedzicha JA. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169: 1298-303.
5. Jones PW, Lamarca R, Chuecos F, et al. Characterisation and impact of reported and unreported exacerbations: Results from ATTAIN. Eur Respir J 2014; 44: 1156-65.